Health Care · Laboratory Analytical Instruments

NAUT Nautilus Biotechnology Inc SEC Filings & Insider Trading Activity 2026

company
CIK 180880544 filings

NAUT at a glance

Nautilus Biotechnology Inc (NAUT, SEC CIK 1808805) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on October 27, 2026, an 8-K current report on October 27, 2026 and Form 4 insider filings as recently as June 22, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 18 institutional investment managers tracked by SignalX reported holding Nautilus Biotechnology Inc (NAUT) shares worth $14.7 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by AH Equity Partners Bio II, L.L.C. on June 2, 2026 of 4,615,974 shares at $2.35 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
18 funds
$14.7M · −2 vs prior quarter
Latest 8-K
Oct 27, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Newly added AIML risk, triggered by platform integration, includes alleged bias, inaccurate outputs, intellectual-property infringement, and evolving regulation
  • Most material update: broadscale assay unavailable for general availability in 2027, prompting resource reallocation toward proteoform applications
  • FDA compliance exposure increased, QMSR effective February 2, 2026, with RUO products potentially subject to clearance or approval requirements
  • Commercialization risk: Voyager pre-orders expected early 2027, with instrument shipments beginning mid-2027
  • Liquidity risk: available resources expected to fund requirements for at least 12 months, alongside a $125.0 million at-the-market program

Management Discussion & Analysis

  • Quarterly revenue $0.2M, versus no material prior-year revenue, driven by $0.2M grant revenue and less than $0.1M service revenue
  • Net loss $15.6M vs $13.6M YoY, with R&D expense $10.2M vs $9.6M and SG&A $6.8M vs $5.9M
  • Cash, cash equivalents and investments $114.3M at September 30, 2026, funding operations and capital expenditures for at least 12 months
  • Operating cash flow use $40.1M vs $38.3M YoY, with $2.4M spent on property and equipment
  • Outlook: pre-orders expected early 2027, shipments mid-2027, broadscale assay delayed beyond 2027 general availability and supply disruptions remain a risk

AI summary of the NAUT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Oct 27, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q3 revenue $0.234M, primarily grants, versus $0 in Q3 2025, signaling an early commercialization stage
  • Operating expenses $16.947M, up 10% year over year, driven by laboratory, professional services, salaries and benefits

Item 2.02: Results of Operations and Financial Condition

  • Press release announces Nautilus Biotechnology’s Q3 2026 financial results for the quarter ended September 30, 2026
  • Investors should review Exhibit 99.1 for reported financial performance and management commentary
Filed Sep 11, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • Up to $125 million common stock ATM offering, enabling flexible capital raising
  • Potential shareholder dilution as shares are sold, with timing and volume controlled by Nautilus

Item 1.02: Termination of a Material Definitive Agreement

  • Termination of TD Cowen sales agreement dated February 28, 2024
  • ATM equity offering program ended, removing TD Cowen as sales agent
Filed Jul 28, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 results for quarter ended June 30, 2026, announced by Nautilus Biotechnology
  • Full financial figures and management commentary in Exhibit 99.1 пресс release

Item EX-99.1: Item EX-99.1

  • First revenue $0.2M, including $0.18M grant revenue and $0.01M service revenue from the first Early Access customer
  • Q2 operating expenses $15.9M, down 7% year over year, while net loss narrowed to $14.5M from $15.0M

AI summaries of NAUT 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for NAUT

Don't miss the next NAUT filing

  • Alerts as it files. A push when NAUT files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut NAUT, by share count.
  • Ask anything. An AI agent that reads every NAUT filing and answers with sources.

NAUT alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
NAZEM FARZADAJun 18, 2026-
Akinsanya KarenAJun 18, 2026-
McIlwain Matthew SAJun 18, 2026-
Epperly Melissa B,AJun 18, 2026-
Posard Matthew L.AJun 18, 2026-
AH Equity Partners Bio II, L.L.C.SellJun 2, 2026$2.35
AH Equity Partners Bio II, L.L.C.SellJun 2, 2026$2.35
Murphy Matthew B.AMar 2, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Net Income-$63.7M-$70.8M-$59.0M
Balance Sheet
Total Assets$305.6M$242.7M$191.1M
Equity$265.4M$208.7M$157.0M
ROE-24.0%-33.9%-37.6%
Per Share
EPS$-0.51$-0.56$-0.47
Cash Flow
Operating CF-$51.7M-$59.1M-$50.7M
CapEx$2.4M$2.1M$1.3M

Source: XBRL data in Nautilus Biotechnology Inc (NAUT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate NAUT share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
NAUT shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202618$14.7M
Q2 202620$20.8M
Q1 202615$27.0M
Q4 202514$12.8M
Q3 202516$6.0M
Q2 202517$5.7M
Q1 202519$6.4M
Q4 202414$11.9M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 133 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

NAUT filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QOct 27, 2026Analysis
8-KOct 27, 2026Analysis-
8-KSep 11, 2026Analysis-
8-KJul 28, 2026Analysis-
10-QJul 28, 2026-
4Jun 22, 2026--
4Jun 22, 2026--
4Jun 22, 2026--
4Jun 22, 2026--
4Jun 22, 2026--
8-KJun 18, 2026--
4Jun 4, 2026-
8-KApr 28, 2026--
10-QApr 28, 2026-
4Mar 4, 2026--
4Mar 4, 2026--
4Mar 4, 2026--
4Mar 4, 2026--
4Mar 4, 2026--
4Mar 4, 2026--
10-KFeb 26, 2026-
8-KFeb 26, 2026Analysis-
10-QOct 28, 2025-
10-QJul 31, 2025-
10-QApr 29, 2025-

Related Health Care companies

All Health Care →

NAUT SEC filings: frequently asked questions

Which institutions hold NAUT stock?

As of September 30, 2026, the largest Nautilus Biotechnology Inc (NAUT) holders among the 13F filers tracked by SignalX were BlackRock ($4.4 million), Vanguard Capital Management LLC ($3.6 million), Renaissance Technologies LLC ($2.3 million), JPMorgan Chase & Co ($1.3 million), State Street Corp ($811,000). 13F-HR reports are filed up to 45 days after each quarter ends.

What did NAUT report in its latest 8-K?

Nautilus Biotechnology Inc (NAUT) filed an 8-K on October 27, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 revenue $0.234M, primarily grants, versus $0 in Q3 2025, signaling an early commercialization stage.

What are the latest NAUT SEC filings?

Nautilus Biotechnology Inc (NAUT) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on October 27, 2026, an 8-K current report on October 27, 2026 and a Form 4 insider filing on June 22, 2026.

What is NAUT's SEC CIK number?

Nautilus Biotechnology Inc (NAUT)'s SEC Central Index Key (CIK) is 1808805. EDGAR lists every NAUT filing under that number.

Ask anything about NAUT

The research agent reads NAUT's filings, financials, insider trades and 13F holders, then answers with sources.